Raluca Ștefana Ioana Moș

Dr. Raluca Ștefana Ioana Moș

Department of Microscopic Morphology/Histology, Angiogenesis Research Center,, Victor Babeş University of Medicine and Pharmacy, Timişoara, Timiş, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PVPaula Alexandra Vulciu
Paula Alexandra Vulciu
LPLuminita Ioana Pilat
Luminita Ioana Pilat
MMMaria-Daniela Mot
Maria-Daniela Mot
PBPaula Irina Barata
Paula Irina Barata
IDImola Donath-Miklos
Imola Donath-Miklos
PMPUSCHITA MARIA
PUSCHITA MARIA
Background: Tetranectin (CLEC3B), a plasminogen-binding protein involved in fibrinolysis and tissue remodeling, has been increasingly studied as a potential diagnostic and prognostic biomarker in cardiovascular disease (CVD). This review synthesizes current evidence on its clinical utility across heart failure (HF), coronary artery disease (CAD), and related conditions. Objectives: To systematically evaluate and synthesize published clinical evidence on the diagnostic and prognostic value of tetranectin in cardiovascular diseases. Methods: A systematic search of PubMed, Google Scholar, and Scopus (January 2010–June 2025) identified original human studies examining associations between tetranectin (CLEC3B) and cardiovascular diseases, including heart failure, coronary artery disease, myocardial infarction, and cardiometabolic conditions. Eligible studies included adult cohorts with observational designs; experimental, in vitro, and pediatric studies were excluded. Two reviewers independently extracted data on study design, population characteristics, biomarker assessment, and outcomes, resolving discrepancies by consensus. Results: Twelve studies were included. Tetranectin levels were consistently lower in patients with CAD, MI, and advanced HF compared to controls. Higher circulating TN levels were associated with reduced risk of HF onset, cardiovascular death, and hospitalization. In two studies, combining tetranectin with NT-proBNP improved diagnostic accuracy over NT-proBNP alone. Mechanistic studies revealed correlations between TN expression and fibrosis-related gene pathways, supporting its biological relevance. Conclusions: Tetranectin shows consistent promise as a diagnostic and prognostic biomarker in cardiovascular disease, particularly in heart failure and coronary artery disease. Its involvement in fibrotic remodeling, plasminogen activation, and vascular homeostasis underlines biological pathways relevance. Combining tetranectin with established biomarkers may improve cardiovascular risk stratification and guide more personalized therapeutic strategies. Further large-scale and longitudinal studies are needed to validate its clinical utility across diverse settings.

5 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CPCalin Pop
Calin Pop
MVManea Viorel
Manea Viorel
LPLucian Liviu Pop
Lucian Liviu Pop
RHRoxana Hodas
Roxana Hodas
LPLavinia Pop
Lavinia Pop
IPIulia Pop
Iulia Pop
Background: The increasing use of routine oncological imaging has led to more frequent detection of incidental pulmonary embolism (PE), potentially modifying the contemporary clinical presentation of cancer-associated pulmonary embolism (CAPE). Methods: We performed a retrospective cohort study including 381 consecutive patients hospitalized with acute PE, of whom 58 had active cancer and 323 had no active malignancy. The primary endpoint was a Severe Hemodynamic Presentation Composite Endpoint (SHPCE), defined as shock, systolic blood pressure < 90 mmHg, and/or high-risk PE according to European Society of Cardiology criteria. Clinical characteristics, severity markers, management strategies, and in-hospital outcomes were compared between patients with CAPE and non-cancer PE (NCPE). Multivariable logistic regression analyses were performed to evaluate factors associated with SHPCE and incidental PE. Results: The patients with CAPE had higher PESI (129.8 ± 29.3 vs. 110.1 ± 32.3; p < 0.001) and sPESI scores (3.03 ± 0.56 vs. 2.68 ± 0.81; p < 0.001), and lower hemoglobin levels (11.7 ± 1.9 vs. 13.2 ± 1.8 g/dL; p < 0.001). Incidental PE was more frequent in CAPE than NCPE cases (13.8% vs. 1.9%; OR 8.45, 95% CI 2.81–25.39; p < 0.001). Despite their higher baseline risk scores, patients with CAPE and NCPE showed similar rates of SHPCE (12.1% vs. 17.6%; p = 0.295), ICU admission (10.3% vs. 11.5%; p = 1.000), and in-hospital mortality (10.3% vs. 11.1%; p = 0.858). In multivariable analyses, right ventricular dysfunction (RVD) showed the strongest association with SHPCE (adjusted OR 10.21, 95% CI 5.34–19.52; p < 0.001), whereas active cancer was not associated with severe presentation. Conclusions: Active cancer was associated with higher clinical risk scores and a greater prevalence of incidental PE but not with increased hemodynamic severity or adverse in-hospital outcomes. Acute PE severity appeared to be more closely related to right ventricular involvement than to cancer status, supporting a severity-based rather than cancer-based approach to risk assessment.

14 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CPCalin Pop
Calin Pop
MVManea Viorel
Manea Viorel
LPLucian Liviu Pop
Lucian Liviu Pop
RHRoxana Hodas
Roxana Hodas
LPLavinia Pop
Lavinia Pop
IPIulia Pop
Iulia Pop
Background: The increasing use of routine oncological imaging has led to more frequent detection of incidental pulmonary embolism (PE), potentially modifying the contemporary clinical presentation of cancer-associated pulmonary embolism (CAPE). Methods: We performed a retrospective cohort study including 381 consecutive patients hospitalized with acute PE, of whom 58 had active cancer and 323 had no active malignancy. The primary endpoint was a Severe Hemodynamic Presentation Composite Endpoint (SHPCE), defined as shock, systolic blood pressure < 90 mmHg, and/or high-risk PE according to European Society of Cardiology criteria. Clinical characteristics, se-verity markers, management strategies, and in-hospital outcomes were compared between patients with CAPE and non-cancer PE (NCPE). Multivariable logistic regression analyses were performed to evaluate factors as-sociated with SHPCE and incidental PE. Results: The CAPE patients had higher PESI (129.8 ± 29.3 vs. 110.1 ± 32.3; p< 0.001) and sPESI scores (3.03 ± 0.56 vs. 2.68 ± 0.81; p< 0.001), and lower hemoglobin levels (11.7 ± 1.9 vs. 13.2 ± 1.8 g/dL; p< 0.001). Incidental PE was more frequent in CAPE than NCPE cases (13.8% vs. 1.9%; OR 8.45, 95% CI 2.81–25.39; p< 0.001). Despite their higher baseline risk scores, patients with CAPE and NCPE showed similar rates of SHPCE (12.1% vs. 17.6%; p=0.295), ICU admission (10.3% vs. 11.5%; p=1.000), and in-hospital mortality (10.3% vs. 11.1%; p=0.858). In multivariable analyses, right ventricular dysfunction showed the strongest association with SHPCE (adjusted OR 10.21, 95% CI 5.34–19.52; p< 0.001), whereas active cancer was not associated with severe presentation. Conclusions: Active cancer was associated with higher clinical risk scores and a greater prevalence of incidental PE but not with increased hemodynamic severity or adverse in-hospital outcomes. Acute PE severity appeared to be more closely related to right ventricular involvement than to cancer status, supporting a severity-based rather than cancer-based approach to risk assessment.